PTC Therapeutics Inc (PTCT)
25.50
+0.29
(+1.15%)
USD |
NASDAQ |
Apr 25, 16:00
25.50
0.00 (0.00%)
After-Hours: 20:00
PTC Therapeutics Enterprise Value: 3.153B for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 3.153B |
| April 23, 2024 | 3.168B |
| April 22, 2024 | 3.211B |
| April 19, 2024 | 3.161B |
| April 18, 2024 | 3.113B |
| April 17, 2024 | 3.149B |
| April 16, 2024 | 3.159B |
| April 15, 2024 | 3.189B |
| April 12, 2024 | 3.246B |
| April 11, 2024 | 3.321B |
| April 10, 2024 | 3.283B |
| April 09, 2024 | 3.336B |
| April 08, 2024 | 3.281B |
| April 05, 2024 | 3.292B |
| April 04, 2024 | 3.353B |
| April 03, 2024 | 3.443B |
| April 02, 2024 | 3.397B |
| April 01, 2024 | 3.412B |
| March 28, 2024 | 3.450B |
| March 27, 2024 | 3.477B |
| March 26, 2024 | 3.364B |
| March 25, 2024 | 3.432B |
| March 22, 2024 | 3.450B |
| March 21, 2024 | 3.533B |
| March 20, 2024 | 3.482B |
| Date | Value |
|---|---|
| March 19, 2024 | 3.553B |
| March 18, 2024 | 3.444B |
| March 15, 2024 | 3.485B |
| March 14, 2024 | 3.435B |
| March 13, 2024 | 3.580B |
| March 12, 2024 | 3.649B |
| March 11, 2024 | 3.573B |
| March 08, 2024 | 3.609B |
| March 07, 2024 | 3.578B |
| March 06, 2024 | 3.587B |
| March 05, 2024 | 3.619B |
| March 04, 2024 | 3.595B |
| March 01, 2024 | 3.669B |
| February 29, 2024 | 3.381B |
| February 28, 2024 | 3.382B |
| February 27, 2024 | 3.390B |
| February 26, 2024 | 3.338B |
| February 23, 2024 | 3.271B |
| February 22, 2024 | 3.193B |
| February 21, 2024 | 3.185B |
| February 20, 2024 | 3.188B |
| February 16, 2024 | 3.183B |
| February 15, 2024 | 3.167B |
| February 14, 2024 | 3.117B |
| February 13, 2024 | 3.050B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.589B
Minimum
Oct 01 2019
4.670B
Maximum
May 22 2023
2.858B
Average
2.803B
Median
Enterprise Value Benchmarks
| Sarepta Therapeutics Inc | 11.22B |
| Catalyst Pharmaceuticals Inc | 1.644B |
| Pfizer Inc | 206.77B |
| Geron Corp | 1.703B |
| Perspective Therapeutics Inc | 984.38M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -155.79M |
| Revenue (Quarterly) | 307.06M |
| Total Expenses (Quarterly) | 303.94M |
| EPS Diluted (Quarterly) | -2.06 |
| Gross Profit Margin (Quarterly) | 90.52% |
| Profit Margin (Quarterly) | -50.74% |
| Earnings Yield | -32.78% |
| Normalized Earnings Yield | -21.77 |